Elan Corp of Ireland has reported net income (excluding one-timecharges of $68 million) of $144.4 million for the first quarter of 2001, a rise of 88.8% compared with the like, year-earlier period, while revenues increased 27% to $429.3 million. The climb was principally due to a jump of 39% in the firm's product revenues to $324.1 million.
Elan's chief executive, Donal Geaney, said the company now has three products which should bring in revenues for the firm of over $100 million each in 2001. These are Zanaflex (tizanidine) for spasticity, Skelaxin (primidone) for muscular pain and the antifungal Abelcet (liposomal amphotericin B).
He added that growth in 2001 will be further boosted by the recently-launched antiepileptic Zonegran (zonisamide) and Myobloc (botulinum toxin type B) for cervical dystonia, Frovelan (frovatriptan) for migraine and ziconotide for chronic severe pain. Mr Geaney also noted that Antegren (natalizumab), which is being developed with Biogen, will enter Phase III clinical trials for multiple sclerosis and Crohn's disease this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze